GLSI (Greenwich LifeSciences) Beta: 1.7966 (As of Jul. 02, 2026)


GLSI Greenwich LifeSciences Inc GLSI
33 GF Score
Price $21.89
! 1 Warning Sign
View Full Analysis

What is Greenwich LifeSciences Beta?

Greenwich LifeSciences GLSI -7.17% 33 Beta is 1.7966 as of Jul. 02, 2026. GuruFocus rates GLSI with a GF Score™ of 33/100. The stock has 1 warning sign investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-02), Greenwich LifeSciences's Beta is 1.7966.


Greenwich LifeSciences  (NAS:GLSI) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Greenwich LifeSciences Beta Related Terms


Greenwich LifeSciences Beta Historical Data

* Premium members only.

The historical data trend for Greenwich LifeSciences's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Greenwich LifeSciences Beta Chart

Greenwich LifeSciences Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial 0.00 0.00 1.04 1.93 2.72

Greenwich LifeSciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.02 1.84 2.67 2.72 2.20

GLSI vs SABS, SRZN, ZNTL: Beta Comparison

For the Biotechnology subindustry, Greenwich LifeSciences's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Greenwich LifeSciences Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Greenwich LifeSciences's Beta distribution charts can be found below:

* The bar in red indicates where Greenwich LifeSciences's Beta falls into.


GLSI
33GF Score
Greenwich LifeSciences Inc GLSI
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Greenwich LifeSciences Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 1.7966 mean?
Greenwich LifeSciences (GLSI) has a Beta of 1.7966 as of Jul. 02, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Greenwich LifeSciences and its competitors.
Is Greenwich LifeSciences' Beta too high?
Greenwich LifeSciences' current Beta is 1.7966. Overall, Greenwich LifeSciences has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Greenwich LifeSciences' Beta compare to SABS and SRZN?
Greenwich LifeSciences' Beta of 1.7966 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Greenwich LifeSciences and its competitors. Greenwich LifeSciences's current Beta is 1.7966. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Greenwich LifeSciences stock overvalued right now?
Greenwich LifeSciences (GLSI) has a current Beta of 1.7966. The current Beta is 1.7966. Greenwich LifeSciences' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Greenwich LifeSciences (GLSI), the current Beta is 1.7966 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Greenwich LifeSciences Business Description

Address 3992 Bluebonnet Drive, Building 14, Stafford, TX, USA, 77477
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
33GF Score

Get the complete analysis for GLSI

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.89
Price